IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA - Free Report) in a research note published on Thursday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $44.00 target price on the stock.

Separately, JPMorgan Chase & Co. lifted their target price on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $53.42.

IDEAYA Biosciences Price Performance

NASDAQ IDYA traded down $0.35 on Thursday, hitting $21.02. 866,629 shares of the stock were exchanged, compared to its average volume of 1,027,369. IDEAYA Biosciences has a 52-week low of $13.45 and a 52-week high of $44.42. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -5.86 and a beta of 0.05. The company's 50-day moving average price is $20.11 and its two-hundred day moving average price is $20.67.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the business earned ($0.53) EPS. Equities analysts predict that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IDYA. CWM LLC raised its position in shares of IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after buying an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after buying an additional 1,546 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of IDEAYA Biosciences during the fourth quarter valued at about $47,000. Signaturefd LLC raised its position in shares of IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after buying an additional 2,271 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after buying an additional 853 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.